Takeda

What Takeda does

Takeda Pharmaceutical Company Limited is a Tokyo-headquartered global biopharmaceutical company founded in 1781, operating across six therapeutic areas: gastroenterology and inflammation, oncology, rare diseases, plasma-derived therapies, neuroscience, and vaccines. The company sells prescription pharmaceuticals to healthcare providers, hospitals, and specialty pharmacies in approximately 80 countries, generating FY2025 revenue of JPY 4,505.7 billion (approximately $28.4 billion), a 1.7% year-over-year decline driven by the August 2023 loss of exclusivity for VYVANSE. Marketed products include ENTYVIO (vedolizumab) for inflammatory bowel disease, HyQvia for primary immunodeficiency, and Amitiza for chronic constipation, while the pipeline is anchored by three near-term launches: zasocitinib (TAK-279, a TYK2 inhibitor acquired from Nimbus Lakshmi for $4 billion), oveporexton (TAK-861, an orexin-2 agonist for narcolepsy type 1 with FDA Priority Review and Q3 2026 PDUFA), and rusfertide for polycythemia vera (NDA under priority review). The oncology pipeline is reinforced by a $1.2 billion upfront / up to $10.2 billion milestone partnership with Innovent Biologics covering IBI363 (PD-1/IL-2α bispecific) and arcotatug tavatecan (CLDN18.2 ADC).

Takeda's revenue model combines prescription product sales, licensing and milestone payments, and royalty streams from co-developed assets. Pricing is set indication-by-indication and payer-by-payer, exemplified by the China launch of bopadacasein gene therapy for hemophilia B at 2.79 million yuan per dose (reduced to 1.39 million yuan), reimbursed through Huimin Insurance. Distribution operates through direct enterprise sales forces targeting gastroenterology, oncology, and rare disease specialists, complemented by regional distributors (notably Adium Pharma in Latin America for non-strategic products) and pharmacy/hospital channels. The company employs approximately 49,000-50,000 people globally and is implementing a transformation program eliminating 4,500 roles to deliver JPY 200 billion ($1.3 billion) in annualized gross savings by FY2028.

Underpinning R&D is an AI-driven drug discovery stack built through partnerships rather than fully in-house development: Insilico Medicine's Pharma.AI platform (PandaOmics for target identification, Chemistry42 for molecular generation), Iambic's NeuralPLexer, Boltz's biomolecular AI models, Schrödinger's computational chemistry platform, and Beacon Biosignals' sleep analytics. Takeda licenses these for AI-assisted molecular design, predictive clinical trial analytics, and structure prediction, with stated intent to compress traditional discovery timelines from years to months. The company is publicly listed on the NYSE (TAK) and Tokyo Stock Exchange (4502) with a market capitalization of approximately $49.7 billion as of mid-2026, and Julie Kim became the first female CEO on June 24, 2026, succeeding Christophe Weber.

Name

Takeda

Legal name

Takeda Pharmaceutical Company Limited

Website

https://takeda.com

Company type

Public

Founded year

1781

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Takeda is a Japan-headquartered global biopharmaceutical company selling specialty prescription medicines across gastroenterology, oncology, rare diseases, neuroscience, and plasma-derived therapies in ~80 countries, with FY2025 revenue of approximately $28.4 billion and a near-term pipeline anchored by zasocitinib, oveporexton, and rusfertide.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Biopharmaceutical medicines
• Prescription pharmaceutical drugs
• Specialty therapeutics
• Plasma-derived therapies
• Oncology drug development

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Takeda generates revenue primarily through the sale of prescription pharmaceutical products across its therapeutic areas including gastroenterology, oncology, rare diseases, neuroscience, and plasma-derived therapies. Revenue is generated through direct sales to healthcare providers, hospitals, and pharmacies globally.
2. Licensing and Milestone Payments: Takeda receives milestone payments from development partnerships (e.g., Protagonist $200M opt-out, potential $775M milestones plus 14-29% royalties on rusfertide) and pays milestones to partners (e.g., $4B upfront for Nimbus TYK2 program).
3. Royalty Revenue from Partnered Products: Takeda receives royalties from products co-developed or licensed to partners, including IBI363 co-commercialization rights with Innovent in the U.S.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Takeda researches, develops, manufactures, and commercializes innovative prescription pharmaceutical products across six therapeutic areas: gastroenterology and inflammation, oncology, rare diseases, plasma-derived therapies, neuroscience, and vaccines. Its portfolio spans marketed biologics and small molecules such as ENTYVIO, HyQvia, and Amitiza, plus late-stage pipeline assets including zasocitinib, oveporexton, and rusfertide. The company also operates BioLife Plasma Services to source plasma for its plasma-derived therapies.

Product overview

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company with a diversified portfolio spanning six therapeutic areas: Gastrointestinal and Inflammation, Rare Diseases, Plasma-Derived Therapies, Oncology, Neuroscience, and Vaccines. The company operates as a platform-plus-products model, combining internal R&D capabilities with strategic external partnerships and acquisitions to develop innovative medicines. Takeda's marketed products include ENTYVIO (vedolizumab) for inflammatory bowel disease, HyQvia for immunodeficiency, and Amitiza for constipation. The pipeline is anchored by three anticipated blockbuster launches: zasocitinib (TAK-279), an oral TYK2 inhibitor acquired for $4 billion that demonstrated Phase 3 superiority over BMS's Sotyktu; oveporexton (TAK-861), an orexin agonist for narcolepsy with FDA Priority Review; and rusfertide for polycythemia vera with NDA submitted. In oncology, Takeda's $11.4 billion partnership with Innovent Biologics includes IBI363 (TAK-928), a PD-1/IL-2 bispecific in Phase 3 for NSCLC, and arcotatug tavatecan, the first CLDN18.2 ADC in regulatory review. The company is also transitioning to an AI-native discovery model through partnerships with Insilico Medicine (up to $600 million) and Iambic Therapeutics (over $1.7 billion). Takeda faces near-term headwinds from VYVANSE loss of exclusivity and is implementing a $1.3 billion cost savings program through workforce reductions.

Differentiator

Problem solved

Functional benefit

Brands

• BioLife Plasma Services: Plasma donation centers operated by Takeda for collecting plasma used in plasma-derived therapies
• HYQVIA
• ENTYVIO
• Oveporexton (TAK-861)
• Zasocitinib (TAK-279)
• Rusfertide

Products and services

• ENTYVIO (vedolizumab) Gut-selective integrin receptor antagonist biologic for moderately to severely active ulcerative colitis and Crohn's disease in adults, with FDA-accepted pediatric sBLA for patients ages 2 and older. Used by gastroenterology specialists and administered via IV infusion.

Quantifiable outcome

• Zasocitinib achieved >35% complete skin clearance at Week 16 vs ~14% for deucravacitinib in head-to-head Phase 3 trial
• +3 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability9 records

Feature5 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• Degron TherapeuticsminorStrategic or Co-development Partner · 6 July 2026Takeda partnered with Degron Therapeutics in a $1.2 billion deal for molecular glue degraders leveraging Degron's AI-driven discovery platform to target previously undruggable proteins for immunology applications.
• Insilico MedicinecoreTechnology or Integration · 2 July 2026Takeda collaboration with Insilico Medicine worth up to $600 million, with Insilico receiving ~$60 million upfront for generative AI drug discovery using Pharma.AI platform across multiple therapeutic areas. Takeda gains exclusive worldwide rights.
• Denali TherapeuticsminorStrategic or Co-development Partner · 6 April 2026Takeda terminated collaboration on DNL593 (progranulin replacement therapy for frontotemporal dementia) for business reasons, returning full rights to Denali.
• Iambic TherapeuticscoreTechnology or Integration · 1 February 2026Takeda partnered with Iambic deploying NeuralPLexer AI platform for novel drug discovery, with potential payments exceeding $1.7 billion.
• Protagonist TherapeuticscoreStrategic or Co-development Partner · 1 January 2026Co-development of rusfertide for polycythemia vera. Protagonist received $200M opt-out payment from U.S. profit-sharing; potential up to $775M in additional milestones and 14-29% tiered royalties upon approval.
• Innovent BiologicscoreStrategic or Co-development Partner · 1 October 2025Takeda paid Innovent $1.2 billion upfront plus up to $10.2 billion in milestones for global co-development and co-commercialization of IBI363 (PD-1/IL-2α bispecific) for oncology. Takeda co-commercializes in U.S. and holds exclusive rights outside greater China.
• Nimbus Therapeutics (Nimbus Lakshmi, Inc.)coreStrategic or Co-development Partner · 8 February 2023Takeda completed acquisition of Nimbus Lakshmi for $4 billion plus milestone payments, incorporating TYK2 program including drug candidate TAK-279 (zasocitinib) for immune-mediated diseases.
• Adaptate BiotherapeuticsminorStrategic or Co-development Partner · 10 January 2022Takeda acquired UK-based Adaptate Biotherapeutics for antibody-based γδ T cell engager platform for immuno-oncology therapies targeting solid tumors.
• Adium Pharma S.A.minorChannel Partner/ Reseller/ Distributor · 16 September 2021Takeda divested non-strategic products in Latin America (Argentina, Colombia, Ecuador, Peru, Central America) to Adium Pharma, maintaining manufacturing and supply for 5 years.
• Shire (Acquisition)coreStrategic or Co-development Partner · 1 January 2019Julie Kim joined Takeda through the Shire acquisition in 2019, bringing plasma-derived therapies business unit and U.S. commercial operations.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Pfizer: Global biopharma with similarly diversified franchises in oncology, inflammation/immunology, vaccines and rare disease; competes with Takeda in IBD/plaque psoriasis, narcolepsy-adjacent CNS and plasma-derived biologics at scale.
• Novartis: Swiss-headquartered, post-Sandoz-spinoff innovator pharma with overlapping focus in immunology, neuroscience and oncology; competes with Takeda's ENTYVIO/zasocitinib, oveporexton and IBI363 portfolios.
• Roche: Diversified pharma + diagnostics with deep specialty pharma presence in oncology, immunology and rare disease; relevant comparator for Takeda's IBI363 oncology bet and AI-driven discovery strategy.
• AstraZeneca: Major innovator pharma with strong oncology and rare-disease franchises, including ADC and bispecific efforts overlapping Takeda/IBI343 and IBI363 programs.
• Johnson & Johnson: Diversified healthcare with significant immunology, oncology and neuroscience overlap; relevant peer for biologic IBD franchise and rare-disease platform economics.
• Sanofi: Global biopharma with a deep specialty-care and rare-disease footprint plus a major vaccine franchise — directly overlapping with several Takeda BUs including rare disease/plasma-adjacent Ig delivery.
• Merck & Co. Keytruda-dominated oncology franchise positions it as the IO benchmark Takeda's IBI363 PD-1/IL-2α bispecific must beat in NSCLC; comparable R&D scale and global commercial infrastructure.
• GSK: Specialty and vaccines-focused global pharma with overlapping immunology and rare-disease commercial models; comparable mix of internal R&D and external partnerships.
• Eli Lilly: Innovator pharma with major franchises in immunology and oncology, plus significant investments in AI/ML-driven discovery; analogous pipeline-replacement dynamics as Takeda wrestles with the VYVANSE cliff.

Direct peers

• Bristol Myers Squibb: Direct head-to-head competitor via Sotyktu (deucravacitinib), whose Phase 3 data zasocitinib just outperformed in plaque psoriasis; broadly competing across hematology/oncology and immunology pipelines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/takeda-pharmaceuticals
• LinkedInlinkedin.com/company/takeda-pharmaceuticals
• Xx.com/takedapharma
• Facebookfacebook.com/takedapharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries5 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A16 records

Investments60 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Takeda